why can compounding pharmacies sell semaglutide Compounded - CanI still get compoundedsemaglutide sem Examining the Role of Compounding Pharmacies in Semaglutide Availability: A Post-Shortage Landscape

How are places still selling compoundedsemaglutide The availability of semaglutide, a popular GLP-1 medication, through compounding pharmacies has been a topic of significant discussion and regulatory scrutiny. Historically, compounding pharmacies played a crucial role in providing access to semaglutide when approved injectable versions like Ozempic® and Wegovy® were experiencing national shortagesNavigating Compounded Semaglutide: What Health Care Providers Need .... This has led to questions about why can compounding pharmacies sell semaglutide, especially as the situation evolves.

Compounding pharmacies are specialized facilities that prepare medications tailored to individual patient needs, often when commercially available drugs cannot meet those specific requirements. They are permitted to sell certain formulations under specific circumstances, primarily when a drug is on the U.S. Food and Drug Administration's (FDA) shortage list. This provision allows them to help patients whose needs aren't met by existing approved drugs.Compounded Semaglutide: Is it worth the risk? During periods of scarcity, compounding pharmacies can sell their versions of medications, offering an alternative for patients and prescribers.

However, the landscape has shifted. The FDA has declared the semaglutide shortage over. Consequently, pharmacies are no longer allowed to regularly make copies of commercially available GLP-1s. This means that, in general, compounding pharmacies can no longer make and sell semaglutide injections as they did previously. The federal Food, Drug, and Cosmetic Act prohibits pharmacies from compounding drug products that are essentially copies of a commercially available drug product.Compounded "semaglutide" is not FDA-approved This restriction is in place because compounded semaglutide versions are not FDA-approved and they are made by licensed pharmacies, but not approved or inspected by the FDA. Consequently, semaglutide was removed from the list, and compounding pharmacies must stop producing their own versions of the drug.Novo Nordisk Calls for FDA to Prohibit Compounding ...

The FDA's stance on compounded semaglutide stems from several concerns.2025年3月3日—As of February 2025,semaglutide was removed from the list, and compounding pharmacies must stop producing their own versions of the drug. Firstly, compounded semaglutide lacks the rigorous FDA-approved clinical trials and quality control measures that branded medications undergo. This means that the dosing can also be less reliable with compounded drugs. Secondly, semaglutide from compounding pharmacies frequently lacks Good Manufacturing Practice (GMP) standards, raising potential safety issues. Reports indicate that the FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeled "for research.Thinking of using a compounding pharmacy? What you ..."

Despite the FDA's directives, some entities continue to offer compounded semaglutideCompounded Semaglutide: Is it worth the risk?. For instance, online telehealth platforms have indicated intentions to continue offering compounded semaglutide to eligible patients. This persistence may involve workarounds, such as combining semaglutide or tirzepatide with additional ingredients, such as vitamin B12FDA has determined the shortage ofsemaglutideinjection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved.. However, it is crucial to understand that these formulations are not the same as FDA-approved injectables. The FDA allows and even encourages compounding pharmacies to produce and sell copycats when a drug is in short supply, but this exception has largely concluded for semaglutide.

The availability of compounded semaglutide outside of its intended purpose as a solution for drug shortages raises further concerns, including potential safety risks.2025年9月25日—FDA has warned companies that have illegallysoldunapproved drugs containingsemaglutide, tirzepatide or retatrutide that are falsely labeled “for research ... Compounding pharmacies are licensed entities, but the medications they produce are not subject to the same level of FDA oversight as commercially manufactured drugs. This lack of approval means that obtaining semaglutide from a non-FDA-approved source not only jeopardizes the patient's health but also carries potential legal ramifications. The manufacturer of FDA-approved semaglutide products, Novo Nordisk, has publicly stated they do not sell their patented semaglutide to compounding pharmacies, meaning these pharmacies cannot be using the branded drug substance.

In summary, while compounding pharmacies were initially permitted to sell semaglutide to help people access treatment during a period of shortage, this is no longer the primary or legal avenue for obtaining these compounded versionsCompounded Semaglutide: Is it worth the risk?. The focus has shifted back to FDA-approved medications, and the pharmacies that continue to offer compounded semaglutide often do so under circumstances that are not aligned with regulatory expectations, driven by concerns due to the potential safety risks associated with unapproved or improperly manufactured drugs. Patients seeking semaglutide should consult with their healthcare provider to discuss FDA-approved options and understand the risks associated with compounded alternativesNovo Nordisk Calls for FDA to Prohibit Compounding ....